Wanbury is currently trading at Rs. 190.50, up by 9.95 points or 5.51% from its previous closing of Rs. 180.55 on the BSE.
The scrip opened at Rs. 181.90 and has touched a high and low of Rs. 191.80 and Rs. 176.65 respectively. So far 15927 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 360.00 on 15-Jul-2026 and a 52 week low of Rs. 162.00 on 27-Jan-2026.
Last one week high and low of the scrip stood at Rs. 191.80 and Rs. 164.15 respectively. The current market cap of the company is Rs. 640.07 crore.
The promoters holding in the company stood at 42.98%, while Institutions and Non-Institutions held 0.73% and 56.28% respectively.
Wanbury has secured the Good Manufacturing Practice (GMP) Compliance Certificate for its Tanuku Plant from Australia's Therapeutic Goods Administration (TGA), the regulatory authority responsible for therapeutic goods in Australia. The certificate covers the manufacturing of the six Active Pharmaceutical Ingredients (APIs) -- Metformin Hydrochloride, Tramadol Hydrochloride, Sertraline Hydrochloride, Diphenhydramine Hydrochloride, Mefenamic Acid and Paroxetine Hydrochloride Hemihydrate.
The certificate was issued on October 28, 2026 and is valid until December 9, 2028, subject to the TGA's applicable re-inspection requirements. With this approval, the TGA will proceed with issuing GMP clearances to Australian sponsors associated with the manufacturing facility, enabling the necessary regulatory clearances for the supply of the approved APIs to the Australian market.
Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.
